Gilead Sciences, Inc. (GILD) financial statements and ratios from SEC XBRL: revenue $29.44B (TTM), net margin 28.9%, revenue growth 4.4% YoY, P/E 19.3. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $29.44B |
| Net Margin | 28.9% |
| Revenue Growth (YoY) | 4.4% |
| EPS Growth (YoY) | 53.8% |
| FCF Growth (YoY) | 46.8% |
| P/E Ratio | 19.3 |
| EV / EBITDA | 17.9 |
| Price / Book | 7.60 |
| Price / Sales | 5.99 |
| FCF Yield | 5.7% |
| DCF Value (model) | $90.24 |
| DCF Upside vs Price | -37.1% |
| Altman Z-Score | 4.45 (safe) |
| Piotroski F-Score | 8/9 |
| Sector P/E (Healthcare) | 21.6 |
GILD overview · GILD earnings · GILD KPIs · GILD investor relations · GILD ownership · GILD peers · GILD filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.